Post-marketing withdrawal of anti-obesity medicinal products because of adverse drug reactions: a systematic review.

Post-marketing withdrawal of anti-obesity medicinal products because of adverse drug reactions: a systematic review.

<h4>Background</h4> <p>We identified anti-obesity medications withdrawn since 1950 because of adverse drug reactions after regulatory approval, and examined the evidence used to support such withdrawals, investigated the mechanisms of the adverse reactions, and explored the trends...

Bibliografski detalji
Glavni autori:	Onakpoya, I, Heneghan, C, Aronson, J
Format:	Journal article
Jezik:	English
Izdano:	BioMed Central 2016

Slični predmeti

Post-marketing withdrawal of analgesic medications because of adverse drug reactions: a systematic review
od: Onakpoya, I, i dr.
Izdano: (2017)

Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature
od: Onakpoya, IJ, i dr.
Izdano: (2016)

Worldwide withdrawal of medicinal products because of adverse drug reactions: a systematic review and analysis
od: Onakpoya, I, i dr.
Izdano: (2016)

Postmarketing withdrawal of human medicinal products because of adverse reactions in animals: a systematic review and analysis.
od: Onakpoya, I, i dr.
Izdano: (2017)

An evidence-based approach to the post-marketing withdrawal of medicinal products because of adverse reactions
od: Onakpoya, I
Izdano: (2017)

Post-marketing regulation of medicines withdrawn from the market because of drug-attributed deaths: An analysis of justification.
od: Onakpoya, I, i dr.
Izdano: (2017)

Pharmacogenetics and adverse drug reactions
od: Ferner, R, i dr.
Izdano: (2010)

An agenda for research on adverse drug reactions.
od: Aronson, J
Izdano: (2007)

Adverse drug reactions--no farewell to harms.
od: Aronson, J
Izdano: (2007)

Publishing histories of adverse reactions to medicaments anecdotally: the PHARMA guidelines for reporting suspected adverse drug reactions.
od: Aronson, J
Izdano: (2008)

Adverse drug reactions: definitions, diagnosis, and management.
od: Edwards, I, i dr.
Izdano: (2000)

Adverse drug reactions: keeping up to date.
od: Aronson, J, i dr.
Izdano: (2002)

Post-marketing drug withdrawals: pharmacovigilance success, regulatory problems : Arrêts de commercialisation de médicaments post-autorisation : succès de la pharmacovigilance, problèmes réglementaires
od: Aronson, J
Izdano: (2017)

Paradoxical reactions: Under-recognized adverse effects of drugs?
od: Hauben, M, i dr.
Izdano: (2006)

National differences in publishing papers on adverse drug reactions.
od: Ferner, R, i dr.
Izdano: (2005)

Distinguishing hazards and harms, adverse drug effects and adverse drug reactions : implications for drug development, clinical trials, pharmacovigilance, biomarkers, and monitoring.
od: Aronson, J
Izdano: (2013)

Case reports of suspected adverse drug reactions--systematic literature survey of follow-up.
od: Loke, Y, i dr.
Izdano: (2006)

Naltrexone‐bupropion (Mysimba®) in management of obesity: A systematic review and meta‐analysis of unpublished clinical study reports
od: Onakpoya, IJ, i dr.
Izdano: (2020)

Meyler's side effects of drugs : the international encyclopedia of adverse drug reactions and interactions /
od: Aronson, Jeffrey K.
Izdano: (2006)

Adverse Drug Reactions: History, Terminology, Classification, Causality, Frequency, Preventability
od: Aronson, J
Izdano: (2012)

Benefits and harms in pivotal trials of oral centrally acting antiobesity medicines: A systematic review and meta-analysis.
od: Onakpoya, I, i dr.
Izdano: (2018)

Stephens' Detection and Evaluation of Adverse Drug Reactions: Principles and Practice
od: Talbot, J, i dr.
Izdano: (2012)

Stephens' Detection and Evaluation of Adverse Drug Reactions: Principles and Practice
od: Talbot, J, i dr.
Izdano: (2012)

Joining the DoTS: new approach to classifying adverse drug reactions.
od: Aronson, J, i dr.
Izdano: (2003)

Pharmacogenomics of cutaneous adverse drug reactions as implication for precision medicine
od: Chun-Bing Chen
Izdano: (2023-01-01)

Adverse drug reactions in a hospital general medical unit meriting notification to the Committee on Safety of Medicines.
od: Smith, C, i dr.
Izdano: (1996)

Unity from diversity: the evidential use of anecdotal reports of adverse drug reactions and interactions.
od: Aronson, J
Izdano: (2005)

Adverse Drug Reactions of Cardiovascular Classes of Medicines—Data for Bulgarian Population
od: Zornitsa Mitkova, i dr.
Izdano: (2024-09-01)

Stephens' detection and evaluation of adverse drug reactions : principles and practice /
od: Talbot, J. C. C., i dr.
Izdano: (2012)

A practical guide to monitoring for adverse drug reactions during antihypertensive drug therapy.
od: McDowell, SE, i dr.
Izdano: (2013)

Preventability of drug-related harms - part II: proposed criteria, based on frameworks that classify adverse drug reactions.
od: Aronson, J, i dr.
Izdano: (2010)

Incomplete evidence: the inadequacy of databases in tracing published adverse drug reactions in clinical trials
od: Derry, S, i dr.
Izdano: (2001)

Incomplete evidence: The inadequacy of databases in tracing published adverse drug reactions in clinical trials
od: Derry, S, i dr.
Izdano: (2001)

Lorcaserin in obesity: minimal benefits and ill-defined harms
od: Onakpoya, I, i dr.
Izdano: (2019)

Social Media as a Source of Information for the Detection of Adverse Drug Reactions in Post-Marketing Surveillance: A Review
od: E. K. Nezhurina, i dr.
Izdano: (2024-12-01)

Health risks of unknown medicines: evidence from adverse drug reactions in Laos
od: Caillet, C, i dr.
Izdano: (2016)

Control of adverse drug reactions in HIV/AIDS antiretroviral treatment with interchangeable medicines
od: M. V. Zhuravleva, i dr.
Izdano: (2018-02-01)

Adherence, adverse drug reactions, and discontinuation associated with adverse drug reactions of HIV post-exposure prophylaxis: a meta-analysis based on cohort studies
od: Shanshan Liu, i dr.
Izdano: (2023-12-01)

Nonsteroidal anti-inflammatory drugs’ adverse drug reactions: 10 years of national database data
od: G. I. Syraeva, i dr.
Izdano: (2022-02-01)

Characteristics of adverse reactions of three anti-glioma drugs in WHO-VigiAccess
od: Huadong Ke, i dr.
Izdano: (2024-10-01)